Students living in residences at the University of Toronto this fall are required to be fully vaccinated and have received at least one booster shot.
Cheryl Regehr, the university's vice-president and provost, and Kelly Hannah-Moffat, the vice-president of people strategy, equity and culture, posted a message addressed to the U of T community on Thursday.
"Recently, U of T reinstated the vaccination requirement for students and employees living in university residences," they said.
"Students living in residences this fall will be required to have a primary series of a COVID-19 vaccine and at least one booster dose before moving in."
U of T students required to have at least 1 COVID-19 booster dose to live in residence (msn.com)
the reason why
The University of Toronto and Moderna, Inc. – known for its mRNA-based COVID-19 vaccine – plan to work together to develop new tools to prevent and treat infectious diseases.
Guided by a partnership framework agreement, the U.S. biotechnology firm will collaborate with U of T researchers who are working across a wide range of fields, including molecular genetics, biomedical engineering, biochemistry and beyond.
The research partnership – Moderna’s first with a Canadian university – was announced Monday during a visit by company executives to U of T’s St. George campus.
Leah Cowen, U of T’s vice-president, research and innovation, and strategic initiatives, said U of T is excited to work alongside Moderna to protect society from current and future health threats.
“Today we are delighted to announce that Moderna is partnering with U of T, and is keen to do so because Moderna recognizes that there is nowhere else in the world where you can find expertise at scale like you can at U of T,” Cowen said during an executive meeting of Moderna and U of T leaders at Simcoe Hall.
“It’s not every day that an opportunity presents to combine a world class life-sciences research community and a disruptive biological innovator. We are proud to say that today is one such day.”
Cowen touted the diversity found at U of T – which reflects that of Toronto, the province and Canada as a whole – as a key strength of our research ecosystem.
“It is this diversity, across our country and across our three campuses, that can propel creative companies like Moderna to flourish,” Cowen said. “We are delighted to have Moderna immersing itself in this burgeoning ecosystem in the coming weeks, months and years.”
Founded in 2010, Moderna is pioneering a new category of medicines made from messenger RNA, or mRNA, which is used by cells to provide instructions to make the proteins that drive human health and treat and prevent disease. Its first commercial product was its COVID-19 vaccine.
U of T partners with Moderna to advance research in RNA science and technology (utoronto.ca)
a case of connecting the dots.
Cheryl Regehr, the university's vice-president and provost, and Kelly Hannah-Moffat, the vice-president of people strategy, equity and culture, posted a message addressed to the U of T community on Thursday.
"Recently, U of T reinstated the vaccination requirement for students and employees living in university residences," they said.
"Students living in residences this fall will be required to have a primary series of a COVID-19 vaccine and at least one booster dose before moving in."
U of T students required to have at least 1 COVID-19 booster dose to live in residence (msn.com)
the reason why
The University of Toronto and Moderna, Inc. – known for its mRNA-based COVID-19 vaccine – plan to work together to develop new tools to prevent and treat infectious diseases.
Guided by a partnership framework agreement, the U.S. biotechnology firm will collaborate with U of T researchers who are working across a wide range of fields, including molecular genetics, biomedical engineering, biochemistry and beyond.
The research partnership – Moderna’s first with a Canadian university – was announced Monday during a visit by company executives to U of T’s St. George campus.
Leah Cowen, U of T’s vice-president, research and innovation, and strategic initiatives, said U of T is excited to work alongside Moderna to protect society from current and future health threats.
“Today we are delighted to announce that Moderna is partnering with U of T, and is keen to do so because Moderna recognizes that there is nowhere else in the world where you can find expertise at scale like you can at U of T,” Cowen said during an executive meeting of Moderna and U of T leaders at Simcoe Hall.
“It’s not every day that an opportunity presents to combine a world class life-sciences research community and a disruptive biological innovator. We are proud to say that today is one such day.”
Cowen touted the diversity found at U of T – which reflects that of Toronto, the province and Canada as a whole – as a key strength of our research ecosystem.
“It is this diversity, across our country and across our three campuses, that can propel creative companies like Moderna to flourish,” Cowen said. “We are delighted to have Moderna immersing itself in this burgeoning ecosystem in the coming weeks, months and years.”
Founded in 2010, Moderna is pioneering a new category of medicines made from messenger RNA, or mRNA, which is used by cells to provide instructions to make the proteins that drive human health and treat and prevent disease. Its first commercial product was its COVID-19 vaccine.
U of T partners with Moderna to advance research in RNA science and technology (utoronto.ca)
a case of connecting the dots.
